JP2024522116A5 - - Google Patents
Info
- Publication number
- JP2024522116A5 JP2024522116A5 JP2023573353A JP2023573353A JP2024522116A5 JP 2024522116 A5 JP2024522116 A5 JP 2024522116A5 JP 2023573353 A JP2023573353 A JP 2023573353A JP 2023573353 A JP2023573353 A JP 2023573353A JP 2024522116 A5 JP2024522116 A5 JP 2024522116A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- antibody construct
- antibody
- muc1
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194597P | 2021-05-28 | 2021-05-28 | |
| US63/194,597 | 2021-05-28 | ||
| PCT/US2022/031431 WO2022251695A2 (en) | 2021-05-28 | 2022-05-27 | Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522116A JP2024522116A (ja) | 2024-06-11 |
| JP2024522116A5 true JP2024522116A5 (cg-RX-API-DMAC7.html) | 2025-05-02 |
| JP7874113B2 JP7874113B2 (ja) | 2026-06-15 |
Family
ID=84230363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573353A Active JP7874113B2 (ja) | 2021-05-28 | 2022-05-27 | Muc1-c/細胞外ドメイン(muc1-c/ecd)に対する多重特異性抗体構築物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262930A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4346890A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7874113B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021828A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117769432A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022283436A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024724A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3220049A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308881A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014109A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251695A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4644413A1 (en) * | 2024-05-03 | 2025-11-05 | Genmab B.V. | Binding agents having altered fc-mediated effector functions |
| WO2026024841A1 (en) * | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| JP5425180B2 (ja) * | 2008-03-27 | 2014-02-26 | ザイモジェネティクス, インコーポレイテッド | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
| MX2011013722A (es) * | 2009-06-18 | 2012-05-08 | Wyeth Llc | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. |
| CA2803391C (en) * | 2010-06-22 | 2021-11-09 | Neogenix Oncology, Inc. | Npc1 antibodies that bind a muc5ac epitope |
| US20150038682A1 (en) * | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| CN106132992B (zh) * | 2014-01-29 | 2020-08-07 | 达娜-法勃肿瘤研究所公司 | 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体 |
| US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
| EP3601357A1 (en) * | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Multispecific antibody constructs binding to muc1 and cd3 |
| US11725060B2 (en) * | 2017-07-20 | 2023-08-15 | Aptevo Reserch and Development LLC | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods |
| AU2018366199A1 (en) * | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| WO2019222428A1 (en) * | 2018-05-16 | 2019-11-21 | Arbele Limited | Composition of bispecific antibodies and method of use thereof |
| EP3850010A1 (en) * | 2018-09-11 | 2021-07-21 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved anti-flt3 antigen binding proteins |
-
2022
- 2022-05-27 US US18/561,413 patent/US20240262930A1/en active Pending
- 2022-05-27 IL IL308881A patent/IL308881A/en unknown
- 2022-05-27 MX MX2023014109A patent/MX2023014109A/es unknown
- 2022-05-27 CN CN202280045669.5A patent/CN117769432A/zh active Pending
- 2022-05-27 BR BR112023024724A patent/BR112023024724A2/pt unknown
- 2022-05-27 CA CA3220049A patent/CA3220049A1/en active Pending
- 2022-05-27 EP EP22812303.0A patent/EP4346890A4/en active Pending
- 2022-05-27 KR KR1020237043964A patent/KR20240021828A/ko active Pending
- 2022-05-27 AU AU2022283436A patent/AU2022283436A1/en active Pending
- 2022-05-27 WO PCT/US2022/031431 patent/WO2022251695A2/en not_active Ceased
- 2022-05-27 JP JP2023573353A patent/JP7874113B2/ja active Active